Aservo^® EquiHaler^®

(ciclesonide inhalation spray)

Details

ASERVO EQUIHALER is a novel glucocorticoid (ciclesonide) delivered via Soft Mist™ inhaler indicated for the management of clinical signs associated with severe equine asthma in horses.

For more information about Aservo EquiHaler please visit AservoEquihaler.com.

Features & Benefits

Features

The activated form of des-ciclesonide is 12 times more potent than dexamethasone based on relative receptor affinity¹
Its SoftMist™ Inhaler technology delivers a potent anti-inflammatory action directly into the lungs in a slow-moving mist
Established “one size fits all” dosing to overcome ‘best guess’ dosing of other inhalation techniques
Designed for horses, the nostril adapter fits gently inside the left nostril of the horse
Easy to administer in three steps: Pierce, Prime and Puff
Single use minimizes risk for cross-contamination between horses

Benefits

Reduced risk of complications that are associated with other glucocorticoids, such as no statistically significant decrease in serum cortisol²
Improved lung function with only a 10-day treatment protocol

Dosage & Administration

Severe equine asthma can only be diagnosed by a veterinarian. Therefore, ASERVO EQUIHALER inhaler can only be prescribed by a veterinarian. However, ASERVO EQUIHALER is made to be easily administered by an owner.

ASERVO EQUIHALER is an all-in-one product, so there is no need to purchase any additional equipment to administer it. The nostril adapter fits inside the horse’s left nostril and the lever is used to release each puff of medication. The product is administered with the left hand, leaving the right hand free to aid in handling the horse. ASERVO EQUIHALER contains enough medication to treat a horse for the labeled 10 days of administration (8 puffs twice a day for 5 days, then 12 puffs once a day for 5 days).

Before using the treatment, make sure to read the product leaflet inside the box carefully and follow the instructions on how to pierce, prime and administer the product safely. The User Manual is also available digitally on AservoEquihaler.com/how-to-use. The scannable QR code on the box and in the user manual provide an instructional video.

How to use ASERVO EQUIHALER

Resources

Find out more at AservoEquihaler.com

For the full Prescribing Information, click here.

Safety Information

ASERVO EQUIHALER inhaler has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing, and nasal irritation/bleeding. Not for use in humans. Keep this and all medications out of the reach of children. In case of accidental inhalation, seek medical advice immediately.

Information for horse owners: After veterinary consultation, please read and understand the entire contents of the user manual for instructions regarding proper handling and use of ASERVO EQUIHALER.

For full safety information visit: AservoEquihaler.com/important-safety-information

IMPORTANT SAFETY INFORMATION:

Safe use of ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares.
In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing, and nasal irritation/bleeding.
Do not use in horses with known hypersensitivity to ciclesonide or corticosteroids.
Corticosteroids may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition.
Administration of corticosteroids may worsen existing bacterial, fungal, or viral infection.
Inhaled corticosteroids should be used with caution, if at all, in horses with active infection of the respiratory tract.
Glucocorticoids should be used with caution in horses with a history of laminitis.
Concurrent use of other anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) or other corticosteroids, should be approached with caution.

HUMAN WARNINGS:

Not for use in humans.
Keep this and all medications out of the reach of children.
In case of accidental inhalation, seek medical advice immediately.
People with known hypersensitivity to ciclesonide or any of the excipients should avoid contact with this veterinary medicinal product.

References

¹ Mukker, J.K., Singh, R.S.P. and Derendorf, H., 2016. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. Journal of pharmaceutical sciences, 105(9), pp.2509-2514.

² Freedom of Information Summary. 2020. Original New Animal Drug Application. Aservo^® EquiHaler^® (ciclesonide inhalation spray).

Trademarks

ASERVO^® and EQUIHALER^® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are the property of their respective owner. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0129-2021

IMPORTANT SAFETY INFORMATION: ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing, and nasal irritation/bleeding. Administration of corticosteroids may worsen existing bacterial, fungal, or viral infection. Glucocorticoids should be used with caution in horses with a history of laminitis, or at a higher risk for laminitis. Not for use in humans. Keep this and all medications out of the reach of children. In case of accidental inhalation, seek medical advice immediately. People with known hypersensitivity to ciclesonide should avoid contact with this product.

INFORMATION FOR HORSE OWNERS: After veterinary consultation, please read and understand the entire contents of the user manual for instructions regarding proper handling and use of ASERVO EQUIHALER.